Premium
Choosing between continuing vitamin K antagonists ( VKA ) or switching to a direct oral anticoagulant in currently well‐controlled patients on VKA for atrial fibrillation: a randomised controlled trial ( GAI nN)
Author(s) -
van Miert Jasper H. A.,
Kooistra Hilde A. M.,
Veeger Nic J. G. M.,
Westerterp Annelies,
PiersmaWichers Margriet,
Meijer Karina
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15856
Subject(s) - apixaban , medicine , vitamin k antagonist , atrial fibrillation , dabigatran , randomized controlled trial , rivaroxaban , stroke (engine) , cardiology , vitamin k , warfarin , mechanical engineering , engineering
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom